Steris (STE) Surges on Upbeat 2027 Guidance and Massive $1 Billion Buyback

Record Results and a Bullish 2027 Roadmap

Steris (STE) emerged as a standout performer in Tuesday's trading session, defying a generally defensive market environment to post a gain of more than 4%. The primary driver behind the move was the company's fiscal 2026 fourth-quarter and full-year earnings report, released late Monday. While the headline earnings per share of $2.83 for the quarter narrowly missed the consensus estimate of $2.86, investors looked past the minor shortfall to focus on the company's aggressive forward-looking guidance. For fiscal 2027, Steris management projected adjusted earnings per diluted share in the range of $11.10 to $11.30, representing a year-over-year increase of 9% to 11%. This outlook notably exceeded Wall Street's expectations, which had been hovering around the $10.22 mark, signaling that the company expects to maintain its growth trajectory despite persistent inflationary pressures and tariff headwinds.

Beyond the earnings figures, the announcement of a new $1 billion share repurchase program served as a significant tailwind for the stock. This authorization replaces the company's previous plan and underscores a high level of confidence from the Board of Directors regarding Steris's cash flow generation and balance sheet strength. In fiscal 2026, the company generated nearly $1 billion in free cash flow, a milestone that provided the necessary capital to both reinvest in the business and return value to shareholders. CEO Dan Carestio highlighted that fiscal 2026 was a record year for the company, with total revenue from continuing operations rising 9% to $5.9 billion. The market's reaction today suggests that the combination of double-digit earnings growth projections and a massive capital return program is more than enough to offset any concerns regarding the slight quarterly miss.

Sector Resilience and Peer Comparisons

The move in Steris comes at a time when the broader MedTech and healthcare equipment sector is showing signs of stabilization following a period of supply chain volatility. Steris's performance is particularly impressive when compared to its peers. For instance, while Steris surged over 4%, other major players in the orthopedic and surgical space saw more muted price action. Zimmer Biomet (ZBH) also made headlines today by increasing its own share repurchase expectations to $1 billion by year-end, yet it did not capture the same level of intraday momentum as STE. Meanwhile, Johnson & Johnson (JNJ) announced the global launch of its next-generation Shockwave C2 Aero catheter, highlighting the ongoing innovation within the sector. Steris's ability to outperform these peers today suggests that investors are specifically rewarding its unique position as a critical infrastructure provider for hospitals and medical device manufacturers.

The underlying strength in Steris's Healthcare segment, which saw revenue grow 7% to $1.14 billion in the fourth quarter, reflects a broader trend of recovering elective procedure volumes globally. As hospitals return to normal operating capacities, the demand for sterilization services, consumables, and surgical equipment remains robust. This "procedure-driven demand" is a theme that has supported the MedTech sector throughout 2026, but Steris's diversified business model—spanning Healthcare, Applied Sterilization Technologies (AST), and Life Sciences—provides a level of stability that few other companies in the space can match. The AST segment, in particular, crossed the $1 billion annual revenue milestone this year, further solidifying Steris's role as an essential partner in the medical device supply chain.

Technical Breakout and Volume Analysis

From a technical perspective, today's move is significant as it pushes STE shares toward the upper end of their recent trading range. The stock opened at $201.95 and steadily climbed throughout the morning, eventually hitting a high of $210.06. This price action has effectively cleared the stock's 50-day moving average of $226.36, which had previously acted as a level of resistance during the spring sell-off. The intraday volume of 456.5K is also tracking well above the typical pace for this time of day, indicating strong institutional participation in the rally. Investors are clearly viewing the $210 level as a key psychological threshold; a sustained close above this mark could open the door for a retest of the 52-week high near $269.44.

The stock's relative strength against the S&P 500 (SPY) is perhaps the most telling aspect of today's trade. With the SPY down 0.59% amid broader concerns about inflation and interest rate policy, Steris's 4.65% outperformance relative to the index marks it as a clear "flight to quality" play. The company's low debt-to-equity ratio of 0.26 and its 20th consecutive year of dividend increases (recently raised to $0.63 per share) make it an attractive option for defensive-minded investors seeking growth in a volatile macro environment. The market is currently pricing in a "beat and raise" story that extends well into the next fiscal year, and the technical setup suggests that the momentum may have further room to run.

Forward Outlook: What to Watch Next

Looking ahead, investors will be closely monitoring Steris's ability to execute on its fiscal 2027 targets. A key component of the company's long-term strategy is the construction of a new sterility assurance manufacturing plant in Mentor, Ohio, which is expected to be operational by late calendar 2027. This facility is intended to expand the company's capacity and drive further efficiencies in the AST segment. Additionally, the market will be watching for any further updates on the impact of tariffs, which management noted trimmed approximately 80 basis points from annual margins in fiscal 2026. If the company can successfully navigate these cost pressures while maintaining its 7-8% projected revenue growth, the current valuation may still offer upside.

Another factor to watch will be the pace of the newly authorized $1 billion buyback. If the company front-loads these repurchases in the coming quarters, it could provide a persistent floor for the stock price. Analysts remain largely bullish on the name, with a median price target of $291.00, implying significant upside from current levels. For now, Steris has proven that its essential role in the healthcare ecosystem and its disciplined capital allocation strategy are powerful drivers of shareholder value, even when the broader market is struggling to find its footing. The next major catalyst for the stock will likely be the first-quarter fiscal 2027 results, where investors will look for confirmation that the procedure-driven demand remains as strong as management currently anticipates.